XML 77 R63.htm IDEA: XBRL DOCUMENT v3.6.0.2
SELECTED QUARTERLY FINANCIAL INFORMATION (UNAUDITED) (Details) - USD ($)
3 Months Ended 12 Months Ended
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Revenues $ 94,000 $ 5,108,000 $ 211,000 $ 749,000 $ 220,000 $ 35,363,000 $ 251,000 $ 537,000 $ 6,162,000 $ 36,371,000 $ 1,153,000
Operating expenses 8,875,000 8,985,000 9,122,000 9,826,000 8,864,000 8,343,000 9,730,000 9,993,000 36,808,000 36,930,000 37,465,000
Net (loss) income $ (8,482,000) $ (3,576,000) $ (8,637,000) $ (8,842,000) $ (8,468,000) $ 27,185,000 $ (9,356,000) $ (9,315,000) (29,537,000) 46,000 (35,670,000)
Basic and diluted net (loss) income per share $ (0.05) $ (0.02) $ (0.05) $ (0.06) $ (0.05) $ 0.17 $ (0.06) $ (0.06)      
License fee revenue                 $ 6,162,000 1,371,000 $ 1,153,000
Collaboration revenue                   $ 35,000,000  
Janssen Pharmaceuticals | License agreements                      
License fee revenue   $ 5,000,000                  
Janssen Biotech | License agreements                      
Collaboration revenue           $ 35,000,000